Effect of Bortezomib on serum cystatin-C in multiple myeloma

Objective The aim of this study was to assess the effect of Bortezomib on serum cystatin-C(Cys-C)in multiple myeloma and whether Cys-C can monitor tumor load.Methods We measured serum Cys-C and β2-microglobulin in multiple myeloma patients and 20 healthy controls pre-and post-Bortezomib therapy.Results Multiple myeloma patients had higher Cys-C and β2-microglobulin levels compared with healthy controls(P0.05).Treatment with Bortezomib produced a significant reduction of cystatin-C and β2-microglobulin,mainly in relapsed patients(P0.05).Conclusion Treatment with Bortezomib can significantly reduce the Cys-C levels,which can be regarded as the potential indicator to monitor tumor load,and β2-microglobulin levels of multiple myeloma patients.